RLAY vs SEPN
RLAY: A precision medicine company using computational drug discovery to target protein motion and advance a pipeline of novel small molecule therapeutics. SEPN: An early-stage biotech company developing cell receptor-targeted therapeutics for inflammation, metabolism, and other diseases through its proprietary chemistry platform.
Side-by-side fundamentals
| Metric | RLAY | SEPN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.27 | $34.20 | |
| Market cap as of 2026-07-23 | $4.2B | $1.5B | |
| Net margin as of 2026-07-23 | -1859.7% | -49.9% | SEPN higher |
| Operating margin as of 2026-07-23 | -2023.7% | -77.1% | SEPN higher |
| ROE as of 2026-07-23 | -43.9% | -9.4% | SEPN higher |
| ROA as of 2026-07-23 | -40.1% | -6.6% | SEPN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +39.0% | +11790.1% | SEPN higher |
| Revenue CAGR (3y) SEC XBRL | +123.2% | +1644.5% | SEPN higher |
| Beta as of 2026-07-23 | 1.67 | 0.62 | |
| 1-year return as of 2026-07-22 close | +431.7% | +173.6% | RLAY higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.